摘要
目的:探讨舒芬太尼复合布托啡诺对乳腺癌根治术患者术后镇痛效果及安全性。方法:将101例乳腺癌根治术患者随机分为观察组及对照组,观察组术后行舒芬太尼复合布托啡诺联合镇痛,对照组术后只用舒芬太尼镇痛;观察HR、MAP、VAS评分、术后24 h静脉自控镇痛(patient-controlled intravenous analgesia,PCIA)按压次数及不良反应情况。结果:两组间T0-T5点的HR、MAP对比差异无统计学意义(P> 0. 05),两组T1-T5点的VAS评分、术后24 h PCIA按压次数对比差均无统计学意义(P> 0. 05),观察组不良反应总发生率低于对照组(P <0. 05)。结论:舒芬太尼复合布托啡诺对乳腺癌根治术患者效果确切,安全性较高。
Objective:To investigate the postoperative analgesic effect and safety of sufentanil combined with butorphanol in patients undergoing radical mastectomy.Methods:101cases of radical mastectomy were divided into the observation group and the control group.The observation group were given sufentanil combined with butorphanol while the control group were given sufentanil only,with the HR,MAP,VAS scores,patient-controlled intravenous analgesia(PCIA)compression times within24h after surgery and the adverse reactions observed.Results:There was no difference in HR and MAP between the two groups from T0to T5(P>0.05).There was no difference in VAS scores from T0to T5and PCIA compression times between the two groups(P>0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:Sufentanil combined with butorphanol has a definite effect on patients undergoing radical mastectomy and it is very safe for patients.
作者
王成龙
王曙
戴慧荣
郭雪进
WANG Chenglong;WANG Shu;DAI Huirong;GUO Xuejin(Department of Anesthesiology,the Third People's Hospital of Yancheng,Yancheng 224001,China)
出处
《包头医学院学报》
CAS
2018年第12期28-29,共2页
Journal of Baotou Medical College